Fairvalue-Calculator Fairvalue-Calculator

PT Enseval Putera Megatrading Tbk., (EPMT) Fair Value & Analysis

Healthcare · ID · Market cap 6.2T IDR

Price2,280 IDR
Fair Value6,153 IDR
Upside+169.9%
Quality95/100
Evidence: High Range 3,674 IDR – 7,890 IDR

Analysis

PT Enseval Putera Megatrading Tbk., (EPMT) currently trades at 2,280 IDR, while our model-based Fair Value estimate is 6,153 IDR — implying the stock looks roughly 169.9% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

PT Enseval Putera Megatrading Tbk., together with its subsidiaries, engages in the distribution and supply of pharmaceutical products, consumer products, medical equipment, cosmetics, and other trading products in Indonesia. The company operates through three segments: Pharmaceutical, Consumer Products, and Others. It also trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, consumable products for hemodialysis therapy, pharmaceutical, medical equipment, and food and beverage; prescription and non-prescription medicines; veterinary products; and operates drug stores, health care clinics, and hemodialysis clinic. In addition, the company provides dental and other equipment; calibration services; distribution and logistics for consumer goods that require cold room temperature handling; transportation and warehousing service using digital platform; information services through web portals and/or digital platforms; healthcare services; end-…

Open the full interactive analysis →

Similar stocks

McKesson Corporation (M1CK34) -80% Cencora, Inc (C1CO34) -89% Cardinal Health, Inc (CAH) -36% Sigma Healthcare Limited (SIGGF) -73% Sitka Gold Corp (SIG) -88% Shanghai Pharmaceuticals Holding (601607) +183%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.